Quality of life (QOL) endpoints are assuming an increasing role in clinical oncology trials. This article reviews the definition of QOL and the importance of measuring QOL in oncology trials. The optimal choice, timing, and frequency of QOL instruments are summarized. Methodologic issues are also reviewed, including the statistical interpretation of QOL data. Finally, the Radiation Therapy Oncology Group clinical outcomes triad model is described. Future QOL studies must focus on randomized trials with clear hypotheses that can lead to clinically meaningful interventions.
aDepartment of Radiation Oncology, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, MI 48202, USA
bDepartment of Radiation Oncology, Boston University Medical Center, Boston, MA, USA